LabGenius Therapeutics | ML-driven Antibody Discovery

Complex antibodies, like multispecifics, are hard to engineer because the relationship between design and function is often non-intuitive. As a consequence, conventional methods are liable to deliver sub-optimal molecules which either fail in the clinic or result in poor patient outcomes.

We’ve developed EVA™— a highly automated discovery engine that enables the rapid identification and co-optimisation of complex therapeutic antibodies across multiple key properties.

Our platform is both modality and format-agnostic but for our internal pipeline, we’re focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. Our novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles.